ASX Penny Stocks to Buy in November

These stocks might be trading for cents but their ambitions are enormous as these ASX-listed penny stocks are turning steady progress into powerful growth stories that investors shouldn’t overlook.

Penny Stocks to Buy in November

Alfabs Australia Limited (ASX: AAL)

Veris Limited (ASX: VRS)

Cynata Therapeutics Limited (ASX: CYP)

Immutep Limited (ASX: IMM)

Alfabs Australia Limited (ASX: AAL)

Alfabs Australia Limited is keeping up its growth pace as a diversified engineering and mining services company.
It had a pretty solid year with expansion in operations as the company posted an EBITDA of around $27.6 million which is 39% higher than last year and a net profit after tax of about $12.2 million.

It was the first full year since the company got listed and demand stayed strong across mining services which helped boost results.

Alfabs also has a solid pipeline of work with projects going on in infrastructure, underground mining and asset repairs as it looks set for steady growth.

Veris Limited (ASX: VRS)

Veris Limited recorded revenue of about $97.2 million and came back to profitability with a profit before tax of around $2.0 million, which is a big change from last year’s loss. 

This recovery mainly comes from shifting focus toward higher margin consulting and digital services which are less price sensitive.

The acquisition of Spatial Vision has made the company stronger in digital consulting and helped it win larger and more valuable contracts while increasing its customer reach.

With a cash balance of $16.6 million and an order book of more than $65 million, Veris looks in a solid position to keep growing. 

Cynata Therapeutics Limited (ASX: CYP)

Cynata Therapeutics Limited is gradually turning into one of the main names in regenerative medicine with its Cymerus platform that makes stem cell treatments from induced pluripotent stem cells.

During FY25 the company showed solid progress in its clinical pipeline, it finished one trial and moved forward with three more that are likely to give results in 2026.

Its clinical work mainly targets big health problems like osteoarthritis, acute graft-versus-host disease and kidney transplantation, all of which are huge global markets worth billions. 

With many late-stage trial outcomes expected within the next year and the demand for cell therapy keeps rising, Cynata looks ready to move from a research stage biotech to possibly becoming a commercial leader in regenerative medicine.

Immutep Limited (ASX: IMM)

Immutep Limited is an Australian biotech company working on new generation immunotherapies that target LAG-3, a protein which controls how the immune system reacts in cancer and autoimmune diseases.

The company’s main focus is eftilagimod alfa (efti), an immune activator which is being tested with global pharma giants like Merck, Pfizer and Novartis.

Immutep’s plan is to grow its immuno-oncology reach through both in-house and partnered projects, backed by its strong IP portfolio.

With few key Phase II and Phase III results expected in 2026, the company is entering an important stage where positive data could lead to major licensing deals.

(Source: Company Announcements)